The Effect Of Individualized Homoeopathic Medicines In Fifty-Millesimal Potency In Treatment Of Seborrheic Dermatitis And Its Relationship With Tubercular Diathesis: An Open-Label, Single-Arm, Prospective Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 37
- Locations
- 1
- Primary Endpoint
- Quality of Life assessment using DLQI (Dermatology Life Quality Index)
Study Overview
Brief Summary
Seborrheic dermatitis (SD) is a common inflammatory skin disease presenting with a papulosquamous morphology in areas rich in sebaceous glands, particularly the scalp, face, and body folds. There are multiple factors associated with the development of SD, and their disparate nature has led to many proposals about its cause and pathogenesis. The onset of SD appears linked to the interplay of normal microscopic skin flora (especially Malassezia spp.), the composition of lipids on the skin surface, and individual susceptibility. Following screening using specific selection(inclusion and exclusion criteria) criteria and obtaining consent , eligible 37 participants will be included in the trial .Individualized Homoeopathic Medicines will be prescribed in 50 millesimal potency after proper case-taking, consultation with Materia medica and Repertory. Following that, the outcomes will be assessed initially at the baseline and every one month up to 3 months as per DLQI scale. The tubercular diathesis assessment will be done based on tubercular diathesis questionnaire.
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Not Applicable
Eligibility Criteria
- Ages
- 18.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Clinically diagnosed cases of SD [ICD Code 11 – EA81.0, EA81.1, 9A06.71]
- •Patient aged 18 – 65 years of all genders
- •Patient not receiving any topical treatment for SD since last 3 months
- •Patients already undergoing homoeopathic treatment for SD, underwent a wash out period of 1.5 months or 6 weeks.
Exclusion Criteria
- •Pregnant or lactating women.
- •Associated systemic or immune compromised illness.
- •Patients who are too sick for consultation.
- •Diagnosed cases of any life threatening, malignant or Psychiatric illness
- •Simultaneous participation in any other clinical trials.
Outcomes
Primary Outcomes
Quality of Life assessment using DLQI (Dermatology Life Quality Index)
Time Frame: At baseline every one month, for 3 months
Secondary Outcomes
- 1. Assessment of tubercular diathesis (TD) and its association with seborrheic(dermatitis by using Tubercular Diathesis questionnaire {approved by)